Correlation Between Genetic and Imaging Information in Patients With Newly Diagnosed Glioblastoma Before Surgery
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | December 2015 |
| Contact: | Ohio State Comprehensive Cancer Center |
| Email: | Jamesline@osumc.edu |
| Phone: | 1-800-293-5066 |
The Correlation Between the Genetic &Amp; Neuroimaging Signatures in Newly Diagnosed Glioblastoma
This pilot clinical trial studies the correlation between the genetics and brain images of
patients with newly diagnosed glioblastoma before surgery. The genetic characteristics of a
tumor are an important way to predict how well it will respond to treatment. Imaging, using
magnetic resonance imaging (MRI), takes detailed pictures of organs inside the body, and may
also provide information that helps doctors predict how brain tumors will respond to
treatment. If MRI can provide doctors with similar information about the tumor as the
tumor's genes, it may be able to be used to predict tumor response in patients whose tumors
cannot be reached by surgery or biopsy to get tissue samples.
patients with newly diagnosed glioblastoma before surgery. The genetic characteristics of a
tumor are an important way to predict how well it will respond to treatment. Imaging, using
magnetic resonance imaging (MRI), takes detailed pictures of organs inside the body, and may
also provide information that helps doctors predict how brain tumors will respond to
treatment. If MRI can provide doctors with similar information about the tumor as the
tumor's genes, it may be able to be used to predict tumor response in patients whose tumors
cannot be reached by surgery or biopsy to get tissue samples.
PRIMARY OBJECTIVES:
I. Determine the correlation between the genetic and neuroimaging signature of glioblastoma.
II. Determine the correlation between the neuroimaging signature of glioblastoma and
prognosis.
OUTLINE:
Patients undergo MRI before and after gadolinium contrast administration, including
3-dimensional (3D) volumetric T1-weighted sequence, fluid attenuated inversion recovery
(FLAIR) sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also
analyzed for the tumor genetic profile.
I. Determine the correlation between the genetic and neuroimaging signature of glioblastoma.
II. Determine the correlation between the neuroimaging signature of glioblastoma and
prognosis.
OUTLINE:
Patients undergo MRI before and after gadolinium contrast administration, including
3-dimensional (3D) volumetric T1-weighted sequence, fluid attenuated inversion recovery
(FLAIR) sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also
analyzed for the tumor genetic profile.
Inclusion Criteria:
- Patients who will be undergoing surgery for newly-diagnosed glioblastoma
- Subtotal, gross total or biopsy patients will be eligible
- Confirmation of pathology as glioblastoma
Exclusion Criteria:
- Tissue analysis demonstrating pathology other than glioblastoma
- Patients with a contraindication to having MR imaging (e.g. pacemaker) or contrast MR
administration (e.g. hypersensitivity to gadolinium or renal insufficiency above the
institutional threshold for administration of contrast); patients with
hypersensitivity to MR contrast may be able to participate if it has been established
that premedication will mitigate the hypersensitivity reaction
We found this trial at
2
sites
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Joseph Helpern, PhD
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Pierre Giglio
Phone: 614-688-7592
Click here to add this to my saved trials